Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.

ABSTRACT:

Background

Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However, the risk of developing cutaneous immune-related adverse events (cirAEs) in patients treated with ICI and TVEC has not been studied.

Objective

To evaluate the differences in cirAE development between patients treated with ICI alone and both ICI and TVEC (ICI + TVEC).

Methods

Patients with cutaneous malignancy receiving ICI with or without TVEC therapy at the Massachusetts General Brigham healthcare system were included. CirAE development, time from ICI initiation to cirAE, cirAE grade, cirAE morphology, and survival were analyzed. Pearson's χ² test or Fisher's exact test for categorical varia

SUBMITTER: Leung BW 

PROVIDER: S-EPMC10796158 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature